Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Intellia Therapeutics Inc shares valued at $38,248 were sold by Dube Michael P on Oct 02 ’24. At $19.01 per share, Dube Michael P sold 2,012 shares. The insider’s holdings dropped to 47,012 shares worth approximately $0.57 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Clark Eliana sold 405 shares, netting a total of over 9,287 in proceeds. Following the sale of shares at $22.93 each, the insider now holds 71,470 shares.
Before that, Verwiel Frank had sold 1,505 shares from its account. In a trade valued at $37,625, the Director traded Intellia Therapeutics Inc shares for $25.00 each. Upon closing the transaction, the insider’s holdings decreased to 1,505 shares, worth approximately $0.22 million.
As published in a research note from Goldman on February 23, 2024, Intellia Therapeutics Inc [NTLA] has been rated down from a Buy to a Neutral and the price target has been revised to $32 from $136. Analysts at Wolfe Research started covering the stock with ‘”a Peer perform”‘ outlook in a report released in mid February. As of April 13, 2023, Canaccord Genuity has initiated its “Buy” rating for NTLA. Earlier on March 21, 2023, Bernstein initiated its rating. Their recommendation was “an Outperform” for NTLA stock.
Analyzing NTLA Stock Performance
During the last five days, there has been a surge of approximately 0.83%. Over the course of the year, Intellia Therapeutics Inc shares have dropped approximately -60.25%. Shares of the company reached a 52-week high of $34.87 on 02/29/24 and a 52-week low of $11.61 on 12/26/24. A 50-day SMA is recorded $15.23, while a 200-day SMA reached $21.34. Nevertheless, trading volume fell to 1.8 million shares from 1.7 million shares the previous day.
Support And Resistance Levels for Intellia Therapeutics Inc (NTLA)
According to the 24-hour chart, there is a support level at 11.74, which, if violated, would cause prices to drop to 11.37. In the upper region, resistance lies at 12.36. The next price resistance is at 12.61. RSI (Relative Strength Index) is 34.53 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.03, which suggests the price will decrease in the coming days. Percent R is at 86.16%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
